Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy

Pertussis is a common respiratory infection caused by the bacterium Bordetella pertussis. Although most cases occur in developing countries, it is considered endemic globally. The World Health Organization estimates there are 20–40 million cases of pertussis annually. Pertussis vaccines played a piv...

Full description

Saved in:
Bibliographic Details
Published in:Medical principles and practice 2022-09, Vol.31 (4), p.313-321
Main Authors: Alghounaim, Mohammad, Alsaffar, Zainab, Alfraij, Abdulla, Bin-Hasan, Saadoun, Hussain, Entesar
Format: Article
Language:English
Subjects:
Age groups
Antigens
Asymptomatic
Epidemics
Epidemiology
Industrialized nations
Infections
Review
Teenagers
Vaccines
Whooping cough
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pertussis is a common respiratory infection caused by the bacterium Bordetella pertussis. Although most cases occur in developing countries, it is considered endemic globally. The World Health Organization estimates there are 20–40 million cases of pertussis annually. Pertussis vaccines played a pivotal role in reducing the burden of pertussis disease as well as infant morbidity and mortality. Although the two forms of pertussis vaccine are effective, each has its advantages and drawbacks. This review aims to review the current knowledge on pertussis vaccines, emphasizing vaccine effectiveness in different populations within a community. Clinical trials have shown favorable vaccine efficacy with acellular pertussis (aP)vaccine. However, observational and population-level studies showed that introducing at least a single dose of whole-cell pertussis (wP) vaccine within the routine immunization schedule is associated with better disease protection and a longer duration of immunity. On the other hand, wP vaccine is more reactogenic and associated with higher adverse events. Therefore, the selection of vaccine should be weighed against the effectiveness, reactogenicity, and cost-effectiveness. Due to its safety profile, aP vaccine can be offered to wider population groups. Booster adolescent and pregnant immunization programs have been implemented globally to control outbreaks and protect vulnerable infants. Due to the variable effectiveness performance of both vaccines, different countries adopted distinctive immunization programs. Determining the right vaccination approach depends on financial consideration, immunization program infrastructure, adverse event monitoring, and pertussis surveillance in the community.
ISSN:1011-7571
1423-0151
DOI:10.1159/000525468